Amendments to the Claims

1(Previously presented). A process for the detection or quantification of eosinophils and basophils, comprising:

bringing a sample, optionally containing said eosinophils or basophils, into contact with an IL-5 anti-receptor (alpha chain) monoclonal antibody produced by the hybridoma deposited with the Collection Nationale de Culture de Microorganisme (CNCM) under accession no. I-2068; and

detecting, and optionally quantifying, the eosinophils and basophils in said sample.

2(Previously presented). A process according to claim 1, wherein the IL-5 anti-receptor monoclonal antibody is an antibody which does not interfere with IgE.

3(Previously presented). A process according to claim 1 or 2, wherein the IL-5 anti-receptor monoclonal antibody is an antibody which does not interfere with the cell activation of eosinophils or basophils.

4(Previously presented). A process according to claim 1 or 2, wherein the detecting step uses a flow cytometer or optical scanning cytometer.

Claim 5 (Cancelled).

6(Previously presented). A process according to claim 19, wherein the other monoclonal antibodies are directed against the markers CD3, CD16 and CD19.

7(Previously presented). A process according to claim 1 or 2, further comprising, for detecting and optionally quantifying activated basophils, bringing the sample into contact with one or more other monoclonal antibodies directed against basophil activation markers.

8(Previously presented). A process according to claim 7, wherein the activation marker is the CD63 antigen.

9(Previously presented). A process according to claim 1 or 2, further comprising, for detecting and optionally quantifying activated eosinophils, bringing the sample into contact with one or more other monoclonal antibodies directed against eosinophil activation markers.

10(Previously presented). A process for the detection and quantification of activated eosinophils according to claim 9, wherein the activation marker is the CD69 antigen.

Claims 11-15 (Cancelled).

16(Previously presented). A process according to claim 1 or 2, wherein the IL-5 anti-receptor monoclonal antibody is an antibody of the IgG1 type, the corresponding hybridoma of which was deposited with the Collection Nationale de Culture de Micro-organismes (CNCM) under accession no. I-2068.

Claim 17 (Cancelled).

18(Previously presented). An IL-5 anti-receptor monoclonal antibody produced by the hybridoma deposited with the

Collection Nationale de Culture de Micro-organismes (CNCM) under accession no. I-2068.

19(Previously presented). A process according to claim 1 or 2, further comprising bringing the sample into contact with other monoclonal antibodies directed against other markers not expressed by the eosinophil or basophil cell types.

20(Currently amended). [[The]] An anti-IL-5R antibody ~~of claim 11~~ which is characterized by:

binding to both eosinophils and basophils;

absence of interference with the fixing of IL-5 to its receptor;

absence of interference with IgE;

absence of interference with cell activation of eosinophils or basophils; and

absence of inhibition of the biological activity of IL5, which is produced by the hybridoma deposited with the Collection Nationale de Cultures de Microorganisme (CNCM) under accession no. I-2068.

21(New). A process according to claim 1, wherein said monoclonal antibody was previously conjugated with a fluorochrome.

22 (New). A kit for the detection or quantification of eosinophils and basophils, comprising:

an anti-IL-5R monoclonal antibody according to claim 18 conjugated to a first fluorochrome; and

a mixture of antibody markers for lymphocytes, monocytes and neutrophils, conjugated to a second fluorochrome.

23 (New). A kit for the detection and quantification of activated eosinophils and basophils, comprising:

an anti-IL-5R monoclonal antibody according to claim 18 conjugated to a first fluorochrome;

a mixture of antibody markers for lymphocytes, monocytes and neutrophils, conjugated to a second fluorochrome; and

antibodies directed against activation markers and conjugated to a third fluorochrome.

24(New). A kit for the detection or quantification of the oxidative activity of eosinophils or basophils, comprising:

an anti-IL-5R monoclonal antibody according to claim 18 conjugated to a first fluorochrome;

a mixture of antibody markers for lymphocytes, monocytes and neutrophils, conjugated to a second fluorochrome; and

a marker substrate for the oxidative activity of eosinophils or basophils.

25(New). A kit according to claim 23 or 24, which is applied to the study of allergic, parasitic or leukaemic pathologies.